Changes in cancer epigenome implicated in chemotherapy resistance, lymphoma relapse
Monday, April 20, 2015 - 14:30
in Health & Medicine
Genomic studies have illuminated the ways in which malfunctioning genes can drive cancer growth while stunting the therapeutic effects of chemotherapy and other treatments. But new findings indicate that these genes are only partly to blame for why treatment that was at one point effective ultimately fails for about 40 percent of patients diagnosed with the most common form of non-Hodgkin's lymphoma.